Every Form 4 that Vertex Pharmaceuticals Inc (VRTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VRTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRTX filings page.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported share sales under a pre-set trading plan. On February 25, 2026, he completed an open-market sale of 668 shares of common stock at $486.35 per share, leaving 18,432 shares held directly afterward.
On February 24, 2026, he disposed of 1,627 shares at $485.11 per share to cover tax obligations by delivering shares, a non-open-market transaction. These transactions were made under a company-approved Rule 10b5-1 trading plan that Mr. Atkinson entered into on August 11, 2025.
Vertex Pharmaceuticals senior executive Kristen Ambrose reported two stock transactions. As SVP & Chief Accounting Officer, she sold 223 shares of Vertex common stock in an open-market sale at an average price of $486.35 per share under a company-approved Rule 10b5-1 trading plan.
She also disposed of 546 shares at $485.11 per share to cover tax obligations by delivering shares rather than cash. After these transactions, she directly held 6,981 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev reported option exercises and share sales. On February 19, 2026, he exercised stock options covering 23,479 shares at a price of $155.57 per share and 25,026 shares at $187.53 per share, converting them into common stock.
On the same date, he sold a total of 58,613 shares of common stock in multiple open-market transactions at prices ranging from approximately $463.91 to $471.43, under a company-approved Rule 10b5-1 trading plan entered into on November 18, 2025. Following these transactions, he held 58,934 shares directly, plus 882 shares in a 401(k) and 9,301 shares held in a trust.
Vertex Pharmaceuticals executive Charles F. Wagner Jr., EVP, Chief Operating Officer and Chief Financial Officer, reported two stock transactions involving the company’s common stock. He received a grant of 7,365 restricted stock units, described as an award that vests in installments beginning on February 20, 2027. This award increased his directly held shares to 51,080 immediately after the grant.
On the same date, Wagner had 2,294 shares of common stock disposed of at $483.75 per share in a transaction coded as a tax-withholding disposition to satisfy tax obligations by delivering securities. After this withholding transaction, his direct ownership stood at 48,786 shares of Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis reported a mix of stock transactions involving company common shares. She received a grant of 5,789 shares as a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 2,294 shares were disposed of to cover tax obligations at a price of $483.75 per share. She also executed open-market sales of 609 shares at $489.46 per share and 368 shares at $473.68 per share, made under a company-approved Rule 10b5-1 trading plan entered on August 21, 2025. Following these transactions, she directly owned 48,650 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev reported mixed equity transactions. He received a grant of 5,789 shares of common stock as a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 2,140 shares were disposed of at $483.75 per share to satisfy tax withholding obligations, leaving him with 69,042 shares held directly, plus additional common stock held indirectly through a 401(k) plan and a trust.
Vertex Pharmaceuticals executive Duncan McKechnie reported a mixed Form 4 transaction involving company stock. He acquired 4,962 shares of common stock on February 17, 2026 through a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 1,148 shares were disposed of at $483.75 per share to cover tax obligations by delivering shares, leaving him with 23,342 shares of common stock held directly.
Vertex Pharmaceuticals Executive Chairman Jeffrey Leiden reported a mix of equity award and tax-related share withholding. On February 17, 2026, he acquired 8,269 shares of common stock at $0.00 per share through a grant described as a restricted stock unit award that fully vested upon grant.
On February 18, 2026, 2,964 shares of common stock at $483.75 per share were disposed of in a tax-withholding disposition, a transaction type used to satisfy tax liabilities by delivering shares rather than an open-market sale. After these transactions, he directly held 38,344 shares of common stock, with an additional 440 shares held indirectly through a 401(k) account.
Vertex Pharmaceuticals CEO Reshma Kewalramani reported mixed equity transactions involving company common stock. She acquired 16,326 shares through a grant or award of restricted stock units, recorded at a price of $0.0000 per share, increasing her direct holdings at that point to 149,813 shares.
On the same date, she disposed of 6,554 shares at $483.75 per share in a tax-withholding disposition to cover exercise price or tax liabilities, leaving her with 143,259 directly held shares afterward. The footnote explains that the restricted stock unit award vests in installments beginning on February 20, 2027, meaning the granted units will become fully available over time rather than immediately.
Vertex Pharmaceuticals executive Mark E. Bunnage reported a mix of stock sales, awards, and tax-related share dispositions. He sold 1,182 shares of common stock at $473.68 per share and 2,437 shares at $489.46 per share in open-market transactions.
He also acquired 2,584 shares through a restricted stock unit award that will vest in installments beginning on February 20, 2027, and disposed of 1,110 shares at $483.75 per share to cover tax obligations. These trades were made under a company-approved Rule 10b5-1 trading plan entered into on November 26, 2025. Following the last reported transaction, he held 8,486 shares of Vertex common stock directly.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic received a grant of 5,375 shares of common stock as a restricted stock unit award that begins vesting on February 20, 2027. On the same date, 1,912 shares at $483.75 each were disposed of to cover tax withholding, leaving her with 41,516 directly owned shares.
Vertex Pharmaceuticals executive Jonathan Biller reported a mix of equity transactions in company stock. On February 17, 2026, he received a grant of 4,135 shares of common stock at $0.00 per share as a restricted stock unit award that vests in installments beginning on February 20, 2027. That same day, 1,505 shares were disposed of at $483.75 per share to cover tax obligations, and 2,476 shares were sold in open-market transactions at an average price of $489.46 per share. On February 18, 2026, he sold an additional 1,244 shares at an average price of $473.68 per share pursuant to an approved Rule 10b5-1 trading plan entered into on February 24, 2025. Following these transactions, he directly held 15,748 shares of Vertex common stock.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported a mix of stock sales, awards, and tax-related share disposals. On February 18, he completed an open‑market sale of 817 shares of common stock at an average price of $473.68 per share, leaving him with 20,727 directly owned shares after that sale.
On February 17, he received a grant of 4,962 shares of common stock at no cost, described as a restricted stock unit award that will vest in installments beginning on February 20, 2027. That same day, 2,031 shares were sold in open‑market transactions at an average price of $489.46 per share, and 1,530 shares were disposed of to cover tax obligations at a price of $483.75 per share. The open‑market sales were executed under a company‑approved Rule 10b5‑1 trading plan entered into on August 11, 2025.
Vertex Pharmaceuticals executive Kristen Ambrose reported several stock transactions involving company common shares. She received a grant of 1,809 shares as a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 598 shares were disposed of to cover tax obligations at a price of $483.75 per share, and 1,557 shares were sold in open-market transactions at $489.46 per share. On the following day, she sold an additional 638 shares at $473.68 per share under a company-approved Rule 10b5-1 trading plan that was entered into on August 8, 2025, leaving her with 7,750 directly owned shares after these transactions.
Vertex Pharmaceuticals executive Charles F. Wagner Jr. reported a tax-related share disposal. On February 13, 2026, he transferred 4,565 shares of common stock at $487.76 per share as a tax-withholding disposition, meaning shares were surrendered to cover taxes rather than sold on the open market. After this transaction, he directly owned 43,715 Vertex shares.
Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions involving company common shares. On February 13, 2026, she disposed of 3,804 shares in a tax-withholding transaction at $487.76 per share and completed an open-market sale of 1,500 shares at a weighted average price of $499.99 per share.
The open-market sale was made under a company-approved Rule 10b5-1 trading plan entered into on August 21, 2025. Following these transactions, she directly owned 46,132 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev, EVP Chief Patient & External Affairs Officer, disposed of 3,548 shares of common stock on February 13, 2026 at $487.76 per share in a tax-withholding disposition. After this, he directly held 65,393 shares, with additional indirect holdings of 9,301 shares in a trust and 882 shares in a 401(k).
Vertex Pharmaceuticals executive Duncan McKechnie reported a tax-related share disposition. On this Form 4, he disposed of 2,283 shares of Vertex common stock on February 13, 2026 at an indicated price of $487.76 per share to cover tax obligations. After this transaction, he directly owned 19,528 shares.
Vertex Pharmaceuticals CEO Reshma Kewalramani reported a Form 4 tax-withholding disposition of 13,041 shares of common stock at $487.76 per share. After this transaction, she directly owns 133,487 Vertex shares.
Vertex Pharmaceuticals executive Mark E. Bunnage reported a tax-related share disposition. On this Form 4, he disposed of 2,283 shares of common stock at a price of $487.76 per share in a transaction coded "F," which represents payment of a tax liability by delivering shares, not an open-market sale. After this transaction, he directly owns 10,631 shares of Vertex common stock.
Vertex Pharmaceuticals executive reports tax-withholding share disposition. EVP and CMO Carmen Bozic disposed of 3,804 shares of Vertex Pharmaceuticals common stock on a tax-withholding basis at $487.76 per share. After this tax-withholding disposition, she directly holds 38,053 shares of Vertex common stock.
Vertex Pharmaceuticals executive Jonathan Biller reported two stock transactions. On February 13, 2026, he disposed of 2,993 shares of common stock at $487.76 per share to cover tax obligations and sold 988 shares in an open-market trade at $499.00 per share. After these transactions, he directly owned 16,838 shares of Vertex common stock. The filing notes the sale was made under a company-approved Rule 10b5-1 trading plan entered into on February 24, 2025.
Vertex Pharmaceuticals director Sangeeta N. Bhatia reported an open-market sale of 266 shares of common stock at $500 per share. After this transaction, she directly owns 4,299 shares. The sale was made under a company-approved Rule 10b5-1 trading plan entered into on 05/27/2025.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported a tax-related share disposition. On February 13, 2026, he disposed of 1,903 shares of Vertex common stock at $487.76 per share as a tax-withholding disposition and now directly holds 20,143 shares of common stock.
Vertex Pharmaceuticals senior executive reports tax-related share disposition
Vertex Pharmaceuticals' SVP & Chief Accounting Officer Kristen Ambrose reported a Form 4 transaction involving a tax-withholding disposition of 1,393 shares of common stock at $487.76 per share on February 13, 2026. This type of transaction reflects shares withheld to cover tax obligations, rather than an open-market sale. After this transaction, Ambrose directly owns 8,734 shares of Vertex common stock.
Vertex Pharmaceuticals executive Charles F. Wagner Jr. reported a tax-related share disposition. On February 10, 2026, he transferred 3,045 shares of Vertex common stock at $468.41 per share under code F, which reflects payment of tax liability by delivering shares.
After this transaction, Wagner directly beneficially owned 48,280 shares of Vertex common stock. The filing characterizes the move as a tax-withholding disposition rather than an open-market purchase or sale.
Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions. On February 11, 2026, she executed an open-market sale of 466 shares of common stock at $460.43 per share, leaving her with 51,436 directly owned shares.
On February 10, 2026, 2,140 shares were disposed of at $468.41 per share to cover tax obligations, a transaction coded as F. The sale was made under a company-approved Rule 10b5-1 trading plan that was entered into on August 21, 2025.
Vertex Pharmaceuticals executive Amit Sachdev reported a tax-related share disposition. On 02/10/2026, 2,057 shares of Vertex common stock were disposed of in a tax-withholding transaction at $468.41 per share. After this, he held 68,941 shares directly.
He also reported indirect ownership of 882 shares through a 401(k) plan and 9,301 shares held in a trust. The filing reflects equity compensation and related tax withholding rather than an open-market trade.
Vertex Pharmaceuticals executive reports tax-withholding share disposition. EVP and Chief Commercial Officer McKechnie Duncan transferred 1,127 shares of Vertex common stock on February 10, 2026 in a tax-withholding disposition priced at $468.41 per share, used to cover tax obligations related to equity compensation.
After this transaction, Duncan directly beneficially owned 21,811 shares of Vertex common stock. The transaction is coded "F," indicating payment of an exercise price or tax liability by delivering already-owned securities rather than an open-market sale.
Vertex Pharmaceuticals CEO & President Reshma Kewalramani reported an automatic share disposition related to taxes. On 02/10/2026, 8,297 shares of Vertex common stock were disposed of at $468.41 per share in a transaction coded "F", which indicates payment of a tax liability by delivering shares rather than a market trade. After this tax-withholding transaction, she directly beneficially owned 146,528 shares of Vertex common stock.
Vertex Pharmaceuticals executive Mark E. Bunnage, EVP and Chief Scientific Officer, reported two transactions in Vertex common stock. On February 11, 2026, he made an open-market sale of 2,021 shares at $460.43 per share. On February 10, 2026, 1,127 shares were disposed of at $468.41 per share to cover tax obligations. After these transactions, he directly owns 12,914 shares of Vertex common stock. The filing notes the sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 26, 2025, indicating the trades were pre-scheduled rather than discretionary.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported a tax-related share disposition. On 02/10/2026, 2,145 shares of Vertex common stock were disposed of at $468.41 per share in a transaction coded "F," which indicates shares were used to satisfy a tax liability. After this transaction, Bozic directly owned 41,857 shares of Vertex common stock.
Vertex Pharmaceuticals executive Jonathan Biller reported share sales and tax-related share dispositions. On 02/11/2026, he sold 1,925 shares of Vertex common stock in an open-market transaction at $460.43 per share under a company-approved Rule 10b5-1 trading plan.
On 02/10/2026, 1,630 shares were disposed of at $468.41 per share to satisfy tax obligations by delivering shares. Following these transactions, Biller directly owned 20,819 shares of Vertex common stock.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer, reported two stock transactions in February 2026. On February 10, 2026, he disposed of 872 shares of common stock to cover tax obligations at a price of $468.41 per share. On February 11, 2026, he executed an open-market sale of 1,751 shares of common stock at $460.43 per share, made under a company-approved Rule 10b5-1 trading plan entered into on August 11, 2025. After these transactions, he directly owned 22,046 shares of Vertex common stock.
Vertex Pharmaceuticals executive Kristen Ambrose reported insider share sales and tax-related share withholding. On February 11, 2026, she completed an open-market sale of 1,376 shares of common stock at $460.43 per share. On February 10, 2026, 592 shares were disposed of at $468.41 per share to cover tax or exercise-related obligations.
Following these transactions, Ambrose directly owned 10,127 shares of Vertex common stock. The sales were made under a company-approved Rule 10b5-1 trading plan that was entered into on August 8, 2025, indicating the trades were pre-arranged rather than discretionary decisions at the time of sale.
Vertex Pharmaceuticals executive Charles F. Wagner Jr., EVP, CO & FO, reported the acquisition of 13,600 shares of Vertex common stock through earned performance awards. On 01/22/2026, he received 9,440 shares tied to a performance stock unit award granted on 02/01/2023 and 4,160 shares from a performance stock unit award granted on 02/12/2025, both at a price of $0 per share.
The company’s management development and compensation committee certified the performance-goal attainment on 01/22/2026. The 2023 award shares will vest on 02/13/2026, while the 2025 award shares will vest in installments beginning on 02/24/2026. Following these transactions, Wagner directly holds 51,325 shares of Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis reported awards of company stock tied to performance goals. On January 22, 2026, she acquired 7,866 shares of Vertex common stock at $0 per share as earned performance shares from a performance stock unit award originally granted on February 1, 2023. On the same date, she also acquired 3,883 shares at $0 per share as earned performance shares from a separate performance stock unit award granted on February 12, 2025. These awards were triggered after the company’s management development and compensation committee certified that the required performance goals had been met, with the 2023 grant scheduled to vest on February 13, 2026 and the 2025 grant scheduled to vest in installments beginning on February 24, 2026. Following these transactions, Tatsis directly beneficially owned 54,042 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev reported new stock awards tied to performance goals. On 01/22/2026, he acquired 7,866 shares of Vertex common stock and another 3,883 shares at a price of $0 per share, reflecting earned performance stock unit awards granted on 02/01/2023 and 02/12/2025 after the compensation committee certified goal attainment on 01/22/2026. Following these awards, he directly holds 70,998 common shares, with additional indirect holdings of 882 shares in a 401(k) plan and 9,301 shares held in trust. The earned performance shares are scheduled to vest on 02/13/2026 and in installments beginning on 02/24/2026.
McKechnie Duncan reported acquisition or exercise transactions in this Form 4 filing.
Vertex Pharmaceuticals executive Duncan McKechnie, EVP and Chief Commercial Officer, reported two equity awards on January 22, 2026, receiving 4,720 and 2,080 shares of common stock at no cash price as earned performance-based stock units. Context notes these shares arise from 2023 and 2025 performance stock unit awards, with performance certified on January 22, 2026 and vesting scheduled in February 2026. Following these grants, he directly holds 22,938 Vertex shares.
Vertex Pharmaceuticals Executive Chairman Jeffrey M. Leiden reported the grant of 9,012 shares of common stock on January 22, 2026. The shares were acquired at a price of $0 as earned performance shares from a performance stock unit award originally granted on February 12, 2025, which was subject to performance-vesting conditions.
The company’s management development and compensation committee certified the level of performance-goal attainment on January 22, 2026, and these shares are scheduled to vest on February 24, 2026. Following this grant, Leiden beneficially owns 33,039 shares of Vertex common stock directly, plus 440 additional shares held indirectly through a 401(k) plan.
Vertex Pharmaceuticals CEO and President Reshma Kewalramani reported two stock acquisitions tied to performance awards. On 01/22/2026, she acquired 26,972 shares of common stock at $0, representing earned performance shares from a performance stock unit award granted on 02/01/2023 after the compensation committee certified performance-goal attainment. These shares will vest on 02/13/2026, bringing her direct holdings to 142,940 shares.
On the same date, she acquired 11,885 additional common shares at $0 as earned performance shares from a separate performance stock unit award granted on 02/12/2025, also following committee certification of performance-goal attainment. These shares will vest in installments beginning on 02/24/2026, increasing her directly held common stock to 154,825 shares.
Vertex Pharmaceuticals executive vice president and CMO Carmen Bozic reported two stock award acquisitions of common stock on 01/22/2026. The filings show grant/award acquisitions of 7,866 and 3,467 shares. Footnotes describe these as earned performance shares from performance stock unit awards granted on 02/01/2023 and 02/12/2025, after the management development and compensation committee certified performance-goal attainment on 01/22/2026, with vesting dates in February 2026. After these awards, she directly holds 44,002 Vertex shares.
Vertex Pharmaceuticals executive Jonathan Biller reported the acquisition of 9,068 shares of common stock through earned performance awards. On 01/22/2026, he received 6,294 shares tied to a performance stock unit grant from 02/01/2023 and 2,774 shares tied to a grant from 02/12/2025, both at a price of $0 per share. The company’s management development and compensation committee certified performance attainment on 01/22/2026. The first block of shares is scheduled to vest on 02/13/2026, and the second will vest in installments beginning on 02/24/2026. Following these awards, Biller directly beneficially owns 24,374 shares of Vertex common stock.
Vertex Pharmaceuticals executive Edward Morrow Atkinson III reported the vesting of performance-based stock awards. On January 22, 2026, he acquired 3,934 shares of Vertex common stock tied to a performance stock unit grant from February 1, 2023, and 3,883 shares tied to a performance stock unit grant from February 12, 2025, both at a price of $0 per share as earned performance shares.
The compensation committee certified achievement of the performance goals on January 22, 2026. The shares from the 2023 grant are scheduled to vest on February 13, 2026, while the 2025 grant will vest in installments beginning on February 24, 2026. Following these transactions, Atkinson directly holds 24,669 shares of Vertex common stock.
Vertex Pharmaceuticals executive Kristen Ambrose, SVP & Chief Accounting Officer, reported the acquisition of company stock tied to performance awards. On 01/22/2026, Ambrose acquired 2,950 shares of Vertex common stock at $0 per share from an earned performance stock unit award originally granted on 02/01/2023, increasing direct holdings to 10,795 shares.
On the same date, Ambrose also acquired 1,300 additional shares at $0 per share from a separate performance stock unit award granted on 02/12/2025, bringing direct ownership to 12,095 shares. The filing explains that these are earned performance shares following the compensation committee’s certification of performance-goal attainment on 01/22/2026, with the related shares scheduled to vest on 02/13/2026 and in installments beginning on 02/24/2026.
Vertex Pharmaceuticals executive David Altshuler reported stock awards tied to performance goals. On 01/22/2026, he acquired 7,866 shares of Vertex common stock and another 3,328 shares, each at a price of $0 per share, reflecting earned performance shares from prior performance stock unit awards. These awards were originally granted on 02/01/2023 and 02/12/2025 and included performance-vesting requirements that the company’s management development and compensation committee certified as achieved on 01/22/2026. After these transactions, Altshuler directly owned 34,477 shares of Vertex common stock. The 7,866-share portion is scheduled to vest on 02/13/2026, and the 3,328-share portion will vest in installments beginning on 02/24/2026.
Vertex Pharmaceuticals director Suketu Upadhyay reported an acquisition of derivative equity on Form 4. On 01/15/2026, he acquired 80.316 deferred stock units at a price of $443.56 per unit, bringing his total holdings of these derivative securities to 2,718.648 units held directly.
Each deferred stock unit represents one share of Vertex common stock and will be paid out in common stock upon the earliest of Mr. Upadhyay’s termination from the board, a change of control of the company, or his disability or death. This filing reflects a change in his deferred equity position rather than an immediate cash transaction in Vertex common shares.
Vertex Pharmaceuticals director Bruce I. Sachs reported an automatic grant of deferred stock units tied to his board service. On January 15, 2026, he acquired 107.088 deferred stock units at a reference price of $443.56 per unit, bringing his total to 15,564.521 deferred stock units held directly.
Each deferred stock unit represents one share of Vertex common stock and will be paid out in common stock at the earliest of Sachs leaving the board, a change of control of the company, or his disability or death. This filing reflects equity-based compensation rather than an open-market stock purchase or sale.
Vertex Pharmaceuticals executive Ourania Tatsis, EVP and Chief Regulatory & Quality Officer, reported selling 4,500 shares of Vertex common stock on 01/07/2026 at a price of $474.99 per share. After this transaction, she beneficially owned 42,293 shares, all held directly.
The filing notes that the sale was made pursuant to Dr. Tatsis’ company-approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025. Such plans are pre-arranged programs that allow insiders to sell stock according to preset terms, helping them diversify holdings while addressing concerns about trading on material nonpublic information.
Vertex Pharmaceuticals executive Charles F. Jr. Wagner, EVP, CO & FO, reported an option exercise and share sale in company stock. On 01/06/2026 he exercised 9,532 stock options at an exercise price of $189.38 per share, receiving the same number of Vertex common shares. That same day, he sold 9,532 common shares at a price of $461 per share, a transaction coded as a sale. After these transactions, he directly owned 37,725 shares of Vertex common stock. The filing notes that the sale was made under Mr. Wagner’s company-approved Rule 10b5-1 trading plan, which was entered into on 05/09/2025, and that the exercised options were fully vested.